WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Biomarkers Inc, a leading developer of protein biomarker analysis systems for pharmaceutical research and development, today announced the formation of a Scientific Advisory Board consisting of internationally renowned scientists and physicians at the forefront of biomarker and clinical research. The Scientific Advisory Board includes:
-- Daniel W. Chan, Ph.D., Director of the Center for Biomarker Discovery and Director, Clinical Chemistry Division, at Johns Hopkins Medical Institution. In addition to his responsibilities of heading the hospital clinical chemistry laboratory, Dr. Chan conducts cutting edge research using state of the art proteomic techniques for biomarker discovery. His overall goals are the identification and characterization of novel biomarkers for the diagnosis and treatment of cancer.
-- Johann de Bono, M.D., Ph.D., Senior Lecturer at The Institute for Cancer Research, Royal Marsden Hospital. Dr. de Bono is leader of the Prostate Cancer Team and directs the clinical drug development Phase I trials program at Royal Marsden Hospital, with a particular interest in pharmacokinetic - pharmacodynamic evaluation of targeted therapeutics.
-- John Heymach, M.D., Ph.D., Assistant Professor of Thoracic Head/Neck
Medical Oncology at the
-- Peter Maimonis, Ph.D. Vice President of Biological Research, Decision
Biomarkers, Waltham, MA. Dr. Maimonis has been involved in the discovery and
validation of tumor biomarkers for over 20 years. His research has focused on
diagnostic markers for breast and colorectal cancer.
|SOURCE Decision Biomarkers Inc|
Copyright©2008 PR Newswire.
All rights reserved